Compare Cassava Sciences Inc (FLNA) vs Ryanair Holdings plc (RYAAY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cassava Sciences Inc vs Ryanair Holdings plc — how do they compare? Cassava Sciences Inc trades at $0.82 (market cap $39.40M), while Ryanair Holdings plc trades at $53.48 (market cap $27.11B). The key difference: Ryanair Holdings plc is far larger — about 688.1× Cassava Sciences Inc's market cap, and Ryanair Holdings plc pays a 1.66% dividend while Cassava Sciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Cassava Sciences Inc for 37 Days and Ryanair Holdings plc for 72 Days on average.
| FLNA | RYAAY | |
|---|---|---|
Market Cap | $39.40M | $27.11B |
Volume | 759,018 | 2,427,380 |
Sector | Health | Industrials |
52-Week High | $4.64 | $73.82 |
52-Week Low | $0.68 | $51.95 |
Typical Hold Time | 37 Days | 72 Days |
Enterprise Value | -$43.28M | $24.18B |
Dividend Yield | — | 1.66% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FLNA trades at $0.8157, down 6.77% today, with a bearish technical signal from moving averages. The company shows improving quarterly EPS trends, beating expectations in recent quarters, though it remains unprofitable with negative ROE and ROA. Recent FDA clearance for its epilepsy drug trial provides a positive catalyst. Analyst sentiment is bullish with 67% buy ratings.
The outlook hinges on clinical progress; upside exists if Phase 2a trials succeed, but high cash burn and lack of revenue pose significant risks. Investors should weigh the strong analyst support against the company's financial challenges and binary clinical outcomes.
RYAAY trades at $56.00, up 0.24% on the day, with a bearish technical signal despite strong fundamentals. The company reported $13.95B revenue and $1.61B net income for 2025, with valuation ratios appearing attractive (P/E 13.43, EV/EBITDA 6.05). Recent news highlights CEO commentary on Boeing MAX 10 delays and fuel cost concerns, while analyst consensus remains positive with 65% buy ratings.
RYAAY presents a value opportunity with solid profitability metrics (ROE 22.41%, net margin 12.13%) but faces near-term headwinds from oil price volatility and operational challenges. The stock's current bearish technical positioning contrasts with fundamental strength, creating potential for recovery if fuel costs stabilize and traffic targets are met.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →About Ryanair Holdings plc
Ryanair is the leading airline group by passenger numbers in Europe. The company employs a low-cost no-frills model to offer low fares to leisure customers on short-haul intra-European routes. In 2020, the most recent pre-pandemic fiscal year, the company carried 149 million passengers, utilizing a fleet of 467 Boeing 737 aircraft across its 1,800 routes. To keep costs low the company serves predominantly lower-cost secondary airports. The company generated sales of EUR 8.5 billion in fiscal 2020.
Read more on RYAAY →
